CereGate

CereGate GmbH (Munich) is a clinical-stage neurotechnology company whose approach is software, not new hardware: its therapy software runs on existing Boston Scientific deep brain stimulation (DBS) systems and is currently in clinical investigation.

What they’re building

Per the company’s own statements:

• the software’s first clinical indication is freezing of gait (FoG), a sudden interruption of walking that persists in some Parkinson’s patients despite optimized medication and responds poorly to established DBS

• separately, the company conducts research in spinal cord stimulation

• CereGate press page (Series C announcement, Oct 14, 2026): ⁰¹

Funding

CereGate announced an oversubscribed Series C on Oct 14, 2026, led by an unnamed “global US-based medtech company,” with Impact Ventures (Budapest) joining as a new investor. No amount was disclosed in the release. The press page also lists existing investors including High-Tech Gründerfonds, 468 Capital, re.Mind Capital, TruVenturo, Heal Capital and CARMA FUND.

• Source: ⁰¹

Notes

• CEO: Matthias Puls (per the release).
• The strategic lead investor is not named in the company release; trade coverage described it the same way.

What to watch

1. Whether the unnamed medtech lead is identified (Boston Scientific itself would be notable given the platform dependency).
2. Clinical readouts for freezing of gait, an indication where standard DBS often fails.